stoxline Quote Chart Rank Option Currency Glossary
PharmaCyte Biotech, Inc. (PMCB)
2.12  -0.05 (-2.3%)    04-17 16:00
Open: 2.12
High: 2.25
Volume: 7,735
Pre. Close: 2.17
Low: 2.12
Market Cap: 18(M)
Technical analysis
2024-04-17 4:48:58 PM
Short term     
Mid term     
Targets 6-month :  2.72 1-year :  3.01
Resists First :  2.33 Second :  2.57
Pivot price 2.33
Supports First :  1.94 Second :  1.61
MAs MA(5) :  2.18 MA(20) :  2.35
MA(100) :  2.2 MA(250) :  2.44
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  8.4 D(3) :  6.7
RSI RSI(14): 40
52-week High :  3.23 Low :  1.91
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PMCB ] has closed above bottom band by 9.7%. Bollinger Bands are 81.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.25 - 2.26 2.26 - 2.27
Low: 2.09 - 2.1 2.1 - 2.12
Close: 2.1 - 2.12 2.12 - 2.14
Company Description

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Headline News

Fri, 12 Apr 2024
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq ... - The Globe and Mail

Tue, 09 Apr 2024
Critical Comparison: PharmaCyte Biotech (NASDAQ:PMCB) vs. Prime Medicine (NYSE:PRME) - Defense World

Wed, 27 Mar 2024
PharmaCyte Biotech (NASDAQ:PMCB) Trading Down 1.6% - Defense World

Fri, 22 Mar 2024
PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business - Simply Wall St

Mon, 18 Dec 2023
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024 - InvestorPlace

Wed, 15 Nov 2023
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 8 (M)
Shares Float 8 (M)
Held by Insiders 8.1 (%)
Held by Institutions 15 (%)
Shares Short 46 (K)
Shares Short P.Month 24 (K)
Stock Financials
EPS -1.49
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.68
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -5.3 %
Return on Equity (ttm) -1.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -2 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -1.44
PEG Ratio 0
Price to Book value 0.57
Price to Sales 0
Price to Cash Flow -8.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android